CIK 0001604464 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue (USD) | 120.8 M | 8.6 M | ||
| Net income (USD) | -228.3 M | -340.1 M | ||
| Diluted EPS (USD/shares) | 2.57 | -65.19 | -2.24 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-09-04 | 4 | FORM 4 | 2026-09-04 |
| 2026-08-26 | 144 | 144 | |
| 2026-08-26 | 4 | FORM 4 | 2026-08-17 |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-12 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-12 | 8-K | 8-K items 2.02 | 2026-08-12 |
| 2026-07-24 | 4 | OWNERSHIP DOCUMENT | 2026-07-22 |
| 2026-07-24 | SCHEDULE 13D/A | SCHEDULE 13D/A | |
| 2026-07-06 | 3 | FORM 3 | 2026-06-26 |
| 2026-06-26 | 8-K | 8-K items 5.02 | 2026-06-22 |
| 2026-06-15 | 4 | FORM 4 | 2026-06-11 |
| 2026-06-15 | 3 | FORM 3 | 2026-06-11 |
| 2026-06-12 | S-8 | REGISTRATION STATEMENT | |
| 2026-06-12 | 8-K | CURRENT REPORT items 5.02,5.07 | 2026-06-09 |
| 2026-06-11 | 4 | FORM 4 | 2026-06-09 |
| 2026-06-11 | 4 | FORM 4 | 2026-06-09 |
| 2026-06-11 | 4 | FORM 4 | 2026-06-09 |
| 2026-05-20 | 4 | 4 | 2026-05-18 |
| 2026-05-20 | 4 | 4 | 2026-05-18 |
| 2026-05-18 | 144 | 144 | |
| 2026-05-18 | 144 | 144 | |
| 2026-05-14 | SCHEDULE 13D/A | SCHEDULE 13D/A | |
| 2026-05-13 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-05-12 | 424B5 | 424B5 | |
| 2026-05-12 | 10-Q | 10-Q | 2026-03-31 |
Forms on file (last 1,000): 4 544, 8-K 139, SC 13G/A 74, 144 36, 10-Q 34, 3 27, 424B5 19, SC 13G 19. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=ATRA (0.002 USD), /gw/filings/filings?ticker=ATRA&form=8-K, /gw/filings/facts?ticker=ATRA&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange